Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized ...

HeartBeam’s latest earnings call struck a cautiously optimistic tone, pairing substantial technical and regulatory momentum with stark financing and execution risks. Management highlighted fresh FDA ...

(MENAFN- Investor Brand Network) HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, reported financial and operational ...

HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment U.S. Food and Drug Administration (FDA) granted 510(k) ...

HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings ALIGN-ACS study expected to complete patient enrollment quickly Milestone signifies ...

HeartBeam's collaboration with Mount Sinai aims to accelerate AI-ECG algorithm development using 3D ECG technology and clinical datasets to enhance remote cardiac monitoring and preventive cardiology.

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in ...

Future indication expansion would unlock large market with over 20 million patients at risk of a heart attack HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming ...

SANTA CLARA, Calif., March 05, 2026--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today ...